Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VTGN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsVistagen reports positive preliminary data from Phase 3 social anxiety disorder trial
Filed May 12, 2026 · Period ending May 12, 2026 · ~1 min read
Key Changes
-
high
Preliminary positive data announced from PALISADE-3 Phase 3 open-label extension study evaluating fasedienol for acute treatment of social anxiety disorder, marking progress in the company's lead drug development program.
Item 8.01 verify on EDGAR → -
high
Results are from the ongoing open-label extension portion of the trial, which follows the controlled phase and provides additional safety and efficacy data over a longer treatment period.
Press Release verify on EDGAR →
Summary
Vistagen Therapeutics announced preliminary positive results from the open-label extension phase of its PALISADE-3 Phase 3 clinical trial studying fasedienol as an acute treatment for social anxiety disorder. This represents a significant milestone in the company's development of its lead drug candidate, as Phase 3 trials are the final stage before potential regulatory approval.
For retail investors, positive Phase 3 data is typically a major catalyst for biotech companies, as it increases the probability of FDA approval and eventual commercialization. The open-label extension provides important longer-term safety and efficacy data that regulators require. However, investors should note these are preliminary results, not final data.
Watch for the company's full data presentation at an upcoming medical conference and any guidance on regulatory filing timelines. The next key milestone will be whether Vistagen announces plans to file a New Drug Application (NDA) with the FDA based on the complete PALISADE-3 dataset.
Section-by-Section Diff
Event · Item 9.01 — Financial Statements and Exhibits
Vistagen filed an 8-K attaching a press release dated May 12, 2026; no material event details disclosed in the filing body.
Added in current filing · verify on EDGAR →
Press Release issued by Vistagen Therapeutics, Inc., dated May 12, 2026
The 8-K references an attached press release dated May 12, 2026, but the filing body provides no details about the content or subject matter of the press release. Without access to Exhibit 99.1, the materiality and nature of the disclosed event cannot be determined from this filing.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify